Dare Bioscience, Inc.
DARE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001401914
No open-market purchases or sales by Dare Bioscience, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.75M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $10.6M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +2 vs. previous quarter
- 27
- 13F valueReported value at the end of Q2 2026
- $2.75M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $1.03M
- +10,429.4% year over year
- Net income, FY2025
- -$13.4M
- No comparable prior period
- Free cash flow, FY2025
- -$10.3M
- −313.0% year over year
- Revenue, Q2 FY2026
- $187.5K
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $13.4M (1300.7% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 986.1K
- Shares sold short
- Change
- −157.6K
- −13.8% vs. previous
- Days to cover
- 6.07
- At average daily volume
Superinvestors holding DARE, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding DARE at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Dare Bioscience, Inc. insiders from Form 4, newest first.
No open-market purchases or sales by Dare Bioscience, Inc. insiders are on file.
Top 10 13F holders, Q2 2026
See all 27 holdersThe largest institutional positions in Dare Bioscience, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 640,877 | $1.35M | 0.00% | +178,572+38.6% | Added |
| Geode Capital Management, LLC | 140,093 | $295.6K | 0.00% | −37,746−21.2% | Reduced |
| US Bancorp | 120,920 | $255.1K | 0.00% | +29,550+32.3% | Added |
| Vanguard Fiduciary Trust Co | 91,269 | $192.6K | 0.00% | +25,331+38.4% | Added |
| BlackRock, Inc. | 64,248 | $135.6K | 0.00% | +47,277+278.6% | Added |
| State Street Corp | 47,415 | $100.0K | 0.00% | +23,900+101.6% | Added |
| Jane Street Group, LLC | 36,092 | $76.2K | 0.00% | +36,092 | New |
| Northern Trust Corp | 34,209 | $72.2K | 0.00% | +18,778+121.7% | Added |
| HRT Financial LP | 22,430 | $47.0K | 0.00% | +22,430 | New |
| Virtu Financial LLC | 15,803 | $33.0K | 0.00% | +15,803 | New |
Holders of 5% or more of DARE
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Dare Bioscience, Inc..